MONTREAL and CHARLOTTE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced upcoming data presentations on etripamil at ISPOR 2024 being held in Atlanta, GA on May 5-8, 2024, the 2024 Stanford BioDesign Arrhythmia Technologies Retreat in Boston, MA, on May 15, 2024, and the Annual meeting of the Heart Rhythm Society, Heart Rhythm 2024, in Boston, MA on May 16-19, 2024. The poster presentations will be available following each embargo at: https://MilestonePharma.com.
| ISPOR | |
| Poster Presentation Title: | Analysis of Healthcare Resource Utilization in the NODE-303 Clinical Trial to Terminate Supraventricular Tachycardia (SVT) Episodes |
| Presenter: | John Jackimiec, RPh., MBA |
| Date and time: | May 6, 3:30 pm EDT |
| 2024 Stanford BioDesign Arrhythmia Technologies Retreat | |
| Poster Presentation Title: | Etripamil Nasal Spray: Data for Acute Rate Control in Atrial Fibrillation with a Rapid Ventricular Rate (AFib-RVR) |
| Presenter: | David Bharucha, MD, PhD, FACC |
| Date and time: | May 15, 10 am EDT |
| Heart Rhythm 2024 | |
| Poster Presentation Title: | Self-Administered Etripamil Nasal Spray Rapidly Terminated Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT): Analysis of Open-Label Treatment in the RAPID Study |
| Presenter: | James Ip, MD, FACC, FHRS |
| Date and time: | May 18, 3:30 pm EDT |
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kim Fox, Vice President, Communications, This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations
Chris Calabrese, This email address is being protected from spambots. You need JavaScript enabled to view it.
Kevin Gardner, This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.82 |
| Daily Change: | -0.02 -2.09 |
| Daily Volume: | 759,393 |
| Market Cap: | US$43.570M |
March 28, 2025 March 20, 2025 March 13, 2025 February 27, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
